|
Dec 15
|
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
|
|
Dec 14
|
UPDATE 2-US CDC says there's urgent need to increase respiratory vaccine coverage
|
|
Dec 14
|
UPDATE 4-AstraZeneca, Sanofi to supply 230,000 more RSV infant shots to US market
|
|
Dec 13
|
Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White House
|
|
Dec 12
|
FTC vs Big Pharma: Sanofi drops Maze deal
|
|
Dec 12
|
Syensqo and Solvay’s $1.7 Billion Surge Makes Case for Spinoffs
|
|
Dec 12
|
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
|
|
Dec 12
|
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
|
|
Dec 12
|
FTC, in unusual move, leads Sanofi to terminate a drug research deal
|
|
Dec 11
|
UPDATE 1-Sanofi terminates deal on drug license after US FTC objects
|
|
Dec 11
|
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
|
|
Dec 11
|
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
|
|
Dec 10
|
25 Most Valuable European Companies Heading into 2024
|
|
Dec 8
|
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
|
|
Dec 7
|
UPDATE 2-US urges makers of infant RSV shots to meet winter demand
|
|
Dec 7
|
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
|
|
Dec 7
|
US urges RSV vaccine makers to meet winter demand, White House says
|
|
Dec 7
|
Sanofi: chief must prove he can win R&D game
|
|
Dec 7
|
UPDATE 2-European shares slip after recent rally, economic worries weigh
|
|
Dec 7
|
UPDATE 2-Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline
|